133 related articles for article (PubMed ID: 26250343)
21. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
Kendler DL; Roux C; Benhamou CL; Brown JP; Lillestol M; Siddhanti S; Man HS; San Martin J; Bone HG
J Bone Miner Res; 2010 Jan; 25(1):72-81. PubMed ID: 19594293
[TBL] [Abstract][Full Text] [Related]
22. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis.
Deng J; Feng Z; Li Y; Pan T; Li Q; Zhao C
Medicine (Baltimore); 2018 Nov; 97(47):e13341. PubMed ID: 30461654
[TBL] [Abstract][Full Text] [Related]
24. Relationship of sclerostin and secreted frizzled protein polymorphisms with bone mineral density: an association study with replication in postmenopausal women.
Valero C; Zarrabeitia MT; Hernández JL; Pineda B; Cano A; García-Pérez MA; Riancho JA
Menopause; 2011 Jul; 18(7):802-7. PubMed ID: 21441835
[TBL] [Abstract][Full Text] [Related]
25. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
Langdahl BL; Marin F; Shane E; Dobnig H; Zanchetta JR; Maricic M; Krohn K; See K; Warner MR
Osteoporos Int; 2009 Dec; 20(12):2095-104. PubMed ID: 19350340
[TBL] [Abstract][Full Text] [Related]
26. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
Tan W; Sun J; Zhou L; Li Y; Wu X
J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
[TBL] [Abstract][Full Text] [Related]
27. The estrogen receptor 1 gene affects bone mineral density and osteoporosis treatment efficiency in Slovak postmenopausal women.
Mondockova V; Adamkovicova M; Lukacova M; Grosskopf B; Babosova R; Galbavy D; Martiniakova M; Omelka R
BMC Med Genet; 2018 Sep; 19(1):174. PubMed ID: 30241506
[TBL] [Abstract][Full Text] [Related]
28. The effect of vitamin D receptor BsmI genotype on the response to osteoporosis treatment in postmenopausal women: a pilot study.
Creatsa M; Pliatsika P; Kaparos G; Antoniou A; Armeni E; Tsakonas E; Panoulis C; Alexandrou A; Dimitraki E; Christodoulakos G; Lambrinoudaki I
J Obstet Gynaecol Res; 2011 Oct; 37(10):1415-22. PubMed ID: 21651652
[TBL] [Abstract][Full Text] [Related]
29. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
Roux C; Binkley N; Boonen S; Kiel DP; Ralston SH; Reginster JY; Pong A; Rosenberg E; Santora A;
Calcif Tissue Int; 2014 Feb; 94(2):153-7. PubMed ID: 23912950
[TBL] [Abstract][Full Text] [Related]
30. Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
Yonsei Med J; 2005 Dec; 46(6):750-8. PubMed ID: 16385649
[TBL] [Abstract][Full Text] [Related]
31. Peripheral quantitative computed tomography is useful to monitor response to alendronate therapy in postmenopausal women.
Sawada K; Morishige K; Nishio Y; Hayakawa J; Mabuchi S; Isobe A; Ogata S; Sakata M; Ohmichi M; Kimura T
J Bone Miner Metab; 2009; 27(2):175-81. PubMed ID: 19152069
[TBL] [Abstract][Full Text] [Related]
32. Analysis of recently identified osteoporosis susceptibility genes in Han Chinese women.
Liu JM; Zhang MJ; Zhao L; Cui B; Li ZB; Zhao HY; Sun LH; Tao B; Li M; Ning G
J Clin Endocrinol Metab; 2010 Sep; 95(9):E112-20. PubMed ID: 20554715
[TBL] [Abstract][Full Text] [Related]
33. Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients.
Iwamoto J; Uzawa M; Sato Y; Takeda T; Matsumoto H
J Bone Miner Metab; 2010 Mar; 28(2):202-8. PubMed ID: 19690798
[TBL] [Abstract][Full Text] [Related]
34. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
Polyzos SA; Anastasilakis AD; Bratengeier C; Woloszczuk W; Papatheodorou A; Terpos E
Osteoporos Int; 2012 Mar; 23(3):1171-6. PubMed ID: 21305266
[TBL] [Abstract][Full Text] [Related]
35. The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis.
Yan Y; Wang W; Zhu H; Li M; Liu J; Luo B; Xie H; Zhang G; Li F
J Bone Miner Metab; 2009; 27(4):471-8. PubMed ID: 19343272
[TBL] [Abstract][Full Text] [Related]
36. Relation of JAGGED 1 and collagen type 1 alpha 1 polymorphisms with bone mineral density in Chinese postmenopausal women.
Zhang LQ; Liu H; Huang XF
Int J Clin Exp Pathol; 2014; 7(10):7142-7. PubMed ID: 25400810
[TBL] [Abstract][Full Text] [Related]
37. Association between polymorphisms in period genes and bone density in postmenopausal Korean women.
Kim H; Koh H; Ku SY; Kim SH; Kim JH; Kim JG
Climacteric; 2014 Oct; 17(5):605-12. PubMed ID: 24678593
[TBL] [Abstract][Full Text] [Related]
38. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
39. Influence of the Osteogenomic Profile in Response to Alendronate Therapy in Postmenopausal Women with Osteoporosis: A Retrospective Cohort Study.
Villagómez Vega A; Gámez Nava JI; Ruiz González F; Pérez Romero M; Trujillo Rangel WÁ; Nuño Arana I
Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833451
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of bone remodelling parameters after one year treatment with alendronate in postmenopausal women with osteoporosis.
Kučukalić-Selimović E; Valjevac A; Hadžović-Džuvo A; Skopljak-Beganović A; Alimanovic-Alagić R; Brković A
Bosn J Basic Med Sci; 2011 Feb; 11(1):41-5. PubMed ID: 21342141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
